Kit of in vitro quantifying large surface protein of hepatitis B virus (HBV), biomarker set for analyzing phases of HBV infection and hepatoma prognosis, and set of monoclonal antibodies for predicting, diagnosing or treating chronic liver disease

A kit of in vitro quantifying large surface protein of hepatitis B virus (LHBS) in a biological sample, comprising:

• a blocking solution;
• a set of monoclonal antibodies for detecting biomarkers in the biological sample, comprising:
• a first monoclonal antibody immobilized in multiple discrete locations on a solid support and immersed in the blocking solution, wherein the first monoclonal antibody has a binding specificity for a first polypeptide listed as SEQ ID NO:
• 1 in a biological sample, and the first monoclonal antibody comprises heavy chain CDR 1 to 3 sequences consisting of SEQ ID NOs:
• 4 to 6 and light chain CDR 1 to 3 sequences consisting of SEQ ID NOs:
• 7 to 9;
• and
• at least one of a second monoclonal antibody and a third monoclonal antibody, wherein the second monoclonal antibody and the third monoclonal antibody are respectively linked to a label, the second monoclonal antibody has a binding specificity for a second polypeptide listed as SEQ ID NO:
• 2 in the biological sample, and the third monoclonal antibody has a binding specificity for a third polypeptide listed as SEQ ID NO:
• 3 in the biological sample, the second monoclonal antibody comprises heavy chain CDR 1 to 3 sequences consisting of the sequences listed as SEQ ID NO:
• 10 to 12 and light chain CDR 1 to 3 sequences consisting of the sequences listed as SEQ ID NO:
• 13 to 15, and the third monoclonal antibody comprises heavy chain CDR 1 to 3 sequences consisting of the sequences listed as SEQ ID NO:
• 16 to 18 and light chain CDR 1 to 3 sequences consisting of the sequences listed as SEQ ID NO:
• 19 to 21;
• and
• a detection reagent capable of reacting with the label and forming a detectable product.